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to decrease toxicity are currently under
investigation. An example is tamoxifen,
which is being tested in clinical trials for
breast cancer prevention at lower than
standard doses and via topical adminis-
tration as a gel directly to the breast to
avoid systemic exposure and resulting
toxicities.In screening for cancer, merging anatomi-
cal speciﬁcity with biological speciﬁcity by
combining molecular with imaging tests
should improve sensitivity as well as spec-
iﬁcity. This improved performance is
expected to reduce the unwanted out-
come of overdiagnosis, so often encoun-
tered in cancer screening.
What challenges exist, even for
cancer prevention approaches
that have been shown to be
effective?
Cancer prevention, in the form of chemo-
prevention, has had major successes,
demonstrated in Phase III randomized
clinical trials (RCTs). The Breast Cancer
Prevention Trial showed that tamoxifen
reduced the risk of breast cancer in
women at high risk by Gail model criteria
by 50%, even more for estrogen receptor-
positive breast cancers. Other agents
demonstrated in Phase III RCTs to reduce
breast cancer risk include the aromatase
inhibitors, anastrozole and exemestane.
Many women at high risk would beneﬁt
from these agents. Clinical experience,
which has been most extensive with pre-
ventive tamoxifen, has revealed a reluc-
tance on the part of appropriate high-risk
individuals and their healthcare providers
to utilize this effective drug for risk reduc-
tion. The main obstacle, which has been
widely investigated, appears to be con-
cern about toxicity in these women who
do not actually have cancer. This brings us
full circle to the core concept of prevention
raised at the beginning of this essay
regarding the importance of determining
the balance of beneﬁts and harms in a
healthy population. This dilemma has
shown the prevention research commu-
nity that we must improve our
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larger community of healthcare providers
and patients truly understands the risk:
beneﬁt trade-offs of these promising can-
cer prevention agents. This leads to the
ﬁnal and central note: we need to help the
public to better understand probabilistic
thinking. Only in this way will they get a
better hold on their risk of future cancer
and appropriate use of preventive inter-
ventions and cancer screening tools.
The responses to the preceding questions
reﬂect discussions that I have had with
Barnett Kramer. In addition to his role as
Director of the Division of Cancer Preven-
tion in the National Cancer Institute, Dr
Kramer is a leader in the ﬁeld of cancer





GenomeFast-paced advances in cancer biology
genomics, and technology have no
Another class of cytotoxic agents that
showed early promise is the so-called,
talways translated rapidly into the swift
development of new cancer therapies.
Changing the landscape of cancer drug
discovery is Paul Workman, CEO and
President of The Institute of Cancer
Research (ICR, London) and Leader of
the Signal Transduction and Molecular
Pharmacology Team in the Cancer
Research UK Cancer Therapeutics Unit
at ICR. Dr Workman spearheads the larg-
est academic drug discovery multidisci-
plinary center, with an unmatched track
record in bringing innovative drug candi-
dates to clinical trials and to patients. Here,
he reﬂects on the challenges and multiple
opportunities ahead and shares his vision
guiding the next decades of cancer drug
research and development.
How has cancer drug discovery
changed over the past decades?
Looking back on this history is incredibly
interesting and informative. I think the
most dramatic difference over the past
ﬁve or six decades, much of which I have
lived through during my own research
career, has been the transition from the
initial period focusing on cytotoxic chemo-
therapy to the modern era of molecularly
targeted drugs. Both periods led to major
improvements in outcomes for patients
with cancer. The chemotherapy era began
during the 1940s and 1950s with the
introduction of drugs that damaged
DNA, often by crosslinking of the Wat-
son-Crick double helix. The initial clinical
success, which saw regressions in lym-
phoid tumors with nitrogen mustard (orig-
inating from chemical warfare work)
introduced in 1942, led to the discovery
and development of chemically less reac-
tive and better tolerated drugs. These
included ICR drugs, such as melphalan,
chlorambucil, and busulphan, as well as
carboplatin, which followed on from cis-
platin (approved for ovarian cancer in
1978); all of these drugs also act as
DNA-damaging agents and crosslinkers,
and each is still in clinical use.
‘antimetabolites’, which work by blocking
the enzymes involved in the synthesis of
DNA from its chemical building blocks.
These include drugs such as methotrex-
ate and 5-ﬂuoruracil, which again are still
widely used. Likewise, many natural prod-
ucts were identiﬁed that block cell division,
for example by binding to tubulin, includ-
ing vincristine, vinblastine, and later pacli-
taxel (Taxol®). In fact, Bristol-Myers
Squib's drug paclitaxel, which was iso-
lated from the bark of the Paciﬁc yew tree
during the1960s and approved in 1992,
was the ﬁrst to be described as a billion-
dollar ‘blockbuster’ oncology drug. Natural
product topoisomerase inhibitors exempli-
ﬁed by irinotecan also came through to the
clinic. These and other cytotoxic agents
were in some cases rationally designed
to act on the drug target, as with antime-
tabolites, or alternatively often were identi-
ﬁed by screening for agents that inhibit
cancer cell division and kill cancer cells,
initially regardless of mechanism, as in
the case of the natural products.
Following signiﬁcant success with alkylat-
ing agents and methotrexate, for example,
as single agents in patients with cancer,
the ﬁrst really big breakthroughs in the
clinic came from the use during the
1960s of the combination of cytotoxic
chemotherapy drugs from different clas-
ses to create a revolutionary curative regi-
men for acute lymphoblastic leukemia in
children and then in Hodgkin's lymphoma
and later non-Hodgkin's lymphoma, both
in adult patients. The main idea was that,
through the combination of mainly cyto-
toxic drugs having distinct cellular mech-
anisms of action and nonoverlapping
adverse effects, one could obtain greater
antitumor beneﬁt while avoiding lethal tox-
icity to the patient. This was important
because the cytotoxic chemotherapy
agents not only kill proliferating cancer
cells, but also destroy rapidly dividing nor-
mal cells, such as in the gut and bone
marrow. The increased anticancer effec-
tiveness of combination chemo, and the
concept that these cocktails could reduce
the occurrence of drug resistance withsingle agents, was supported by experi-
ence of using combination therapy to suc-
cessfully treat infectious diseases, such as
tuberculosis, and later HIV.
Much of the clinical progress was under-
pinned by lab research in mouse leukemia
models and valuable concepts such as
scheduling and maximizing fractional cell
kill. After the early success in leukemias
and lymphomas, the continued use of
cytotoxic drug combinations also began
to impact treatment of more common
solid tumors, such as breast and colorec-
tal cancer. This fascinating era of cytotoxic
chemotherapy is well described in Vincent
DeVita's recent book The Death of Can-
cer, which also covers the personalities
and politics involved in US President Nix-
on's so-called ‘War on Cancer’ during the
1970s. I wrote a three-part essay about all
this in my blogi.
Although still widely used and valuable
clinically, the big limitation of the cytotoxic
chemo drugs is their killing of all rapidly
dividing cells, giving rise to severe adverse
effects and, hence, a narrow therapeutic
window. Also, there is the problem of drug
resistance, even with a combination of
cytotoxic drugs in cocktails. Furthermore,
these are usually one-size-ﬁts all treat-
ments with little or no ability to predict
which particular patients will respond.
Just as there was a realization that cyto-
toxic drugs had reached a plateau in their
effectiveness, the next real clinical break-
through came from the introduction of
targeted therapies. These new therapies
were based on our growing understand-
ing of the causal molecular mechanisms
underpinning cancer and very much
exploited the extraordinary discoveries
of the many genes and signaling pathways
that are hijacked by cancer cells. That
knowledge has come from basic, funda-
mental, blue-skies research that in fact
beneﬁted greatly from the increased fund-
ing allocated to the War on Cancer since
1971. The period during the 1970s and
1980s was the initial heyday for thediscovery of oncogenes and tumor sup-
pressor genes.
What do you see as the main
milestones and challenges for
impactful personalized drug
discovery?
There was in fact a frustrating 20-year gap
before academic researchers and the
pharmaceutical industry converted our
growing knowledge of the fundamental
basis of cancer into the exciting new wave
of molecularly targeted drugs, starting
with the approval in 1998 of trastuzumab
(Herceptin®), a monoclonal antibody that
binds to the extracellular domain of the
oncogenic HER2 receptor tyrosine kinase
and used to treat HER2-positive meta-
static breast cancer. Next, in 2001, Novar-
tis's BCR-ABL kinase tyrosine kinase
inhibitor imatinib (Glivec) was approved
for BCR-ABL-positive chronic myeloid
leukemia. Here, we had a small-molecule
drug that speciﬁcally blocked the single,
translocated, activated oncogene product
that drives the disease and totally trans-
formed the outcome for patients. It was
followed by the small molecules geﬁtinib
(Iressa®), which I was involved in while at
AstraZeneca, and also erlotinib (Tar-
ceva®), both of which inhibit the epidermal
growth factor receptor (EFGR) tyrosine
kinase. An important breakthrough with
these drugs was the discovery in 2004
that it was patients with non-small lung
cancer whose tumors harbored onco-
genic activating mutations in EGFR who
responded to them. Meanwhile, cetuxi-
mab (Erbitux®), a monoclonal antibody
that acts on the extracellular domain of
EGFR, was approved for combination
therapy in colon cancer in 2004. It was
later shown only to be active in patients
with KRAS wildtype cancers. The ﬁrst clin-
ically proven antiangiogenic drug bevaci-
zumab (Avastin®) is another antibody, in
this case to vascular endothelial growth
factor (VEGF), which was approved for
colon cancer in 2004.
This was an incredibly exciting time. Prog-
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DNA repair defects.increased fundamental knowledge about
the molecular basis of what we now call
the ‘Hallmarks of Cancer’, and the even-
tual shift in therapeutic mindset that I men-
tioned above, but also by technological
advances, such as high-throughput
screening and structure-based drug
design for small-molecule inhibitors as well
as recombinant DNA technology for bio-
logical agents. The new wave of biotech-
nology companies, such as Sugen, whose
researchers I worked closely with and also
many others, such as Amgen and Gen-
entech, had a big impact. Improved ani-
mal models had an important role,
although these are still by no means per-
fect, progressing from mouse leukemias
as the main screening model through
human tumor cell line panels (latterly molec-
ularly characterized) and conventional
human tumor xenografts and then geneti-
cally engineered mouse models all the way
to the current favorites, which are organoid
cultures and more freshly produced patient-
derived xenografts (PDXs). In retrospect, I
think the 20-year delay between the discov-
ery of SRC and other oncogenic kinases
and the approval of the ﬁrst kinase inhibitor
drug was caused by the need to switch the
collective mindset of the oncology ﬁeld,
especially but not solely in industry, away
from the cytotoxic paradigm to what we
now variously call stratiﬁed, personalized,
or precision molecular medicine. Notably
of course, it was bridged by the antiestro-
gens, initially tamoxifen (a failed contracep-
tive), for the treatment of estrogen receptor-
positive breast cancer, which was in fact
initially approved in the UK as early as 1972,
despite the focus on cytotoxic chemo at
that time.
How are patients with cancer
beneﬁting from ‘drugging the
genome’ approach?
I think I am responsible for coining this term
‘drugging the cancer genome’ and pro-
mulgating it in my talks and reviews! I ﬁnd
it a useful term conceptually to describe
the new genome-centric approach that
has dominated the cancer drug discovery
horizon from 2000 to now. What we have
I think I can best answer this by ﬁrst
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in the pace and scale at which cancer
genes have been discovered, most espe-
cially as a result of the revolution in high-
throughput genome sequencing. This was
ﬁrst exempliﬁed in the UK Cancer Genome
Project's identiﬁcation of mutant BRAF as
a major oncogene in melanoma, which led
rapidly to the discovery and approval of
BRAF and MEK inhibitors for that disease.
Further rapid progress has been made by
international efforts, such as the The Can-
cer Genome Atlas consortium.
In parallel, also important has been the co-
development of companion biomarkers for
patient selection, which is crucial for the
implementation of personalized medicine.
At the simplest level, this involved having a
companion biomarker assay for a single
predictive marker, for example, a BRAF
mutation or HER2 ampliﬁcation. Beyond
that, many patients now beneﬁt from
sequencing large numbers of cancer
genes through gene panel tests and, in
many instances, whole-exome or entire
genome sequencing as well as gene
expression proﬁling, with treatment deci-
sions being made based on this. This has
for example been valuable in identifying
mechanisms underlying exceptional
responders or resistance to targeted ther-
apies. I hope that we are moving towards
routine gene panel and whole-exome/
genome sequencing to guide therapy in
a routine setting.
Beyond predictive assays, target engage-
ment biomarkers and additional biomark-
ers of downstream biochemical and
biological effects have been critical in
informing go/no go decision-making and
the selection of dose and schedule of
administration for molecularly targeted
agents. I have codiﬁed this within a con-
ceptual and practical framework that I
christened the ‘Pharmacological Audit
Trail’, which has proved valuable.Drugging the cancer genome has pro-
gressed beyond the now common devel-
opment of drugs that block the function ofdriver oncogenes to include the approach
of synthetic lethality, as exempliﬁed by the
approval in 2014 of olaparib for patients
with ovarian cancer with BRCA mutations,
and its exciting potential in patients with
prostate cancer with BRCA and otherHowever, there is still a long way to go in
drugging the cancer genome before we
can say that we are even approaching
genome-scale coverage. We need to
continue to expand the number of cancer
gene defects for which we have corre-
sponding drugs. Although there are
around 500 cancer-causing proteins,
for example as listed in the Catalogue
of Somatic Mutations in Cancer (COS-
MIC), we only have drugs for about
5% of these. We need to focus more
effort on discovering innovative drugs
that act on currently untargeted cancer
proteins, as opposed to developing ‘me
too’ drugs that simply reproduce the
effects of existing medicines. Many can-
cer genes are technically hard to drug
because of the absence of readily drug-
gable pockets or protein–protein interac-
tions, but the envelope of druggability is
being greatly extended, as shown by the
inhibitors of the BCL2 family. In general,
tumor suppressor genes are tough to
drug but synthetic lethal opportunities
are now available. Standout examples
of cancer genes that are not yet drugged
are RAS, MYC and P53. We have to get
drugs for all the key cancer genes if we
are to approach the aspirational goal of
routine genome sequencing for all
patients with cancer and linking this to
the choice of personalized single drugs
or combinations for all cancer genome
states.
What are the principles behind
running a large successful
academic drug discovery team?speaking from my own personal experi-
ence of building and running such a team
and then broadening to more general
observations.
running high-throughput screens, but also
requires considerable investment and
multidisciplinary team science expertise
to go all the way from target discovery
through and into the clinic. Collaboration
and partnership is essential. Within the
new culture in industry of outsourcing
innovation, there is increasing potential
for academic drug discovery to have a
valuable role in the ecosystem.
What are the priorities over the
next decade in cancer drug
discovery?
I think it is worth noting that the War on
Cancer, as articulated during the 1970s,
greatly underestimated the difﬁculty of
treating more than 200 different cancers
that have, as we now know, even greater
genetic subdivisions. In addition, the
expectation of discovering what some
perceived would be a single magic bulletI came to ICR in 1997 to be Director of the
Cancer Research UK (CRUK) Therapeu-
tics Unit. I had previously spent around 20
years in academia at the University of
Leeds, the MRC Oncology Unit at Cam-
bridge, a brief sabbatical at Stanford and
SRI International, and then in Glasgow as
Director of Laboratory Research in Medi-
cal Oncology at the Beatson Laboratory.
Rather unusually for that time, from 1993
to 1997, I then spent 4 years in a senior
leadership position at AstraZeneca (then
called Zeneca) discovering drugs acting
on new molecular targets, including geﬁ-
tinib, and also initiating and running the
strategic alliance on kinase inhibitors with
Sugen. Throughout all this time, my focus
had been on new drug discovery and
development: straddling the end of the
cytotoxic era, targeting tumor hypoxia,
discovering early kinase inhibitors and
other signaling inhibitors, and then running
a wide range of projects in industry.
I came to the conclusion that something
was missing in the ecosystem. Industry
tended to be rather risk averse and reluc-
tant to take on early-stage projects where
proof of concept for novel targets was
lacking. There was also increasing pres-
sure to consider commercial aspects and
blockbuster potential at too early a stage.
Academia was reasonably comfortable
with early risk but lacked resources, ﬁre-
power, professional project leadership,
and especially medicinal chemistry skills,
multidisciplinary team science experience,
and industrial nouse. I felt that there was a
need for a hybrid construct. Being driven
by a combination of intense curiosity
about cancer science and an equally
strong desire to make a difference for
patients with cancer (not least since my
father had died from colorectal cancer), I
was attracted by the opportunity offered
by ICR to build a large drug discovery
team in academia that combined the
respective strengths of academic and
industrial research. There was already a
small drug discovery group at ICR thathad successfully discovered clinical can-
cer drugs, mainly chemotherapy agents,
and there was support for me to continue
that culture while also modernizing in
terms of technologies and focusing on
new molecular targets. Over time, we
grew the Unit to around 160 staff, of which
about half were core-funded on a 5-year
renewable program grant from CRUK,
providing important critical mass, stability,
and ﬂexibility to run a portfolio of projects.
Also important was the implementation of
what is referred to as the ‘centre of dis-
ease excellence model’, which combines
(i) close collaboration and cutting-edge
basic research as source of targets
(through ICR, CRUK, and beyond); (ii)
equally close interaction with clinical can-
cer specialists (through ICR and our clini-
cal partner the Royal Marsden Hospital);
and (iii) the recruitment of experienced
drug discovery scientists from both aca-
demia and industry. Importantly, our drug
discovery leaders have full faculty status
within ICR and are required to publish
high-quality papers as well as discover
chemical biology probes and drugs.
Critically, since we are not commercially
driven, we see our mission as tackling
high-risk projects and obtaining preclinical
or clinical proof of concept, before partner-
ing with industry at the right time for each
project. We put great emphasis on robust-
ness and reproducibility in our thorough
target validation using orthogonal methods
with both genetic tools and chemical
probes. While operating industry-like mul-
tidisciplinary project teams with milestone-
driven objectives, we at the same time can
give promising projects time and resource
to succeed rather than killing them too
early. We recognize the importance of get-
ting the right people to work together. We
have a clear strategy but recognize that
getting the right discovery and translational
culture is even more important.
Success is shown by our discovery since
2005 of 20 preclinical drug candidates,
progress of nine of these into clinical trials,and achieving the regulatory approval of
the CYP17 inhibitor abiraterone, discov-
ered at ICR and trialed clinically at the Royal
Marsden, for treatment of advanced pros-
tate cancer. We have also won numerous
awards, including the AACR Team Science
prize in 2012, which I am specially proud of.
Over the next 5 years, the Unit is embracing
the tough challenge of overcoming cancer
evolution and drug resistance. Probably the
biggest challenge we face is ﬁnding sufﬁ-
cient funding to bridge the ‘Valley of Death’
between identifying a preclinical candidate
drug and progressing it rapidly through to
early clinical trials. We are identifying and
helping to create various innovative funding
mechanisms to bridge the gap. Now that I
am Chief Executive of and President of ICR,
we have recruited Raj Chopra from Cel-
gene to lead this next phase.
Thinking about academic drug discovery
more broadly, I think it is encouraging to
see this model developing elsewhere. I
believe that many of the above learning
points are applicable in other places. I
think there is increasing recognition that
academic drug discovery is not only aboutTrends in Cancer, October 2016, Vol. 2, No. 10 547
cure for all these different cancers in 5
years was of course hopelessly ill-con-
ceived. Medical and scientiﬁc challenges
are always tough to crack and timescales
for breakthroughs are difﬁcult to predict.
Despite this, real progress has been
made. For example, ﬁgures for the UK
show that overall cancer survival is now
double what it was during the 1970s,
with more than half of all patients with
cancer surviving 10 years or more. Che-
motherapy and molecularly targeted
drugs have certainly had an important
role in that.
By contrast, survival of many cancers,
such as those of the lung, pancreas, gul-
let, and brain, is still very poor indeed. The
5-year survival for lung cancer in the UK is
less than 10%
I think that without doubt the biggest pri-
ority both in the clinic and in cancer
research is understanding and overcoming
the challenges of treatment resistance,
which is commonly driven by genetic insta-
bility leading to tumor heterogeneity and
clonal evolution. At my own Institute, we
have positioned this challenge front and
central in our new research strategy for
2016-2021ii.
Resistance commonly involves Darwinian
selection, but rather than the survival of
the ﬁttest, I refer to this as ‘the survival of
the nastiest’, which seems more appro-
priate. The selective pressure for such
malign evolution can be provided by the
adverse conditions of the tumor microen-
vironment and also unfortunately by drug
therapy. There are a number of ways to
tackle this enduring problem. First of all,
we need to extend the druggable cancer
genome as I described earlier. Second,
we need to consider that targeting driver
oncogenic kinases and epigenetic regula-
tors may routinely provide only 3–6
months of valuable life extension before
resistance develops. This indicates to me
that oncogenic drivers should not be the
sole focus of our drug discovery efforts548 Trends in Cancer, October 2016, Vol. 2, No. 10and targeting non-oncogene addiction
mechanisms could be a valuable part of
the mix, as exempliﬁed by proteasome
inhibitors for example. Third, we must dis-
cover the most effective drug combina-
tions. By using drugs in appropriate
cocktails, we can hopefully cut off can-
cer's evolutionary escape routes. These
combinations will need to include enhanc-
ing the immune response against the can-
cer. Indeed, the approval of immune
checkpoint inhibitors has been the stand-
out breakthrough of the past few years.
Fourth, we need to discover cancer net-
work drugs. Network drugs tackle more
than one of the cellular signaling pathways
that are hijacked in cancer. These drugs
can hit cancer harder than drugs targeted
to only one protein, because they can act
on several targets at once. One example I
am interested in is the use of HSP90
molecular chaperone inhibitors that show
promise in clinical trials against drug-resis-
tant cancers, including lung tumors driven
by exon 20-mutant EGFR. Our own drug
called luminespib that we discovered at
ICR in collaboration with Vernalis is show-
ing promising activity in this type of cancer,
which is unresponsive to other drugs.
Although we now recognize that drug
resistance arising through adaptive mech-
anisms and clonal evolution will be an
enduring problem, I think that our increas-
ing understanding of the mechanisms
underlying resistance will allow us to focus
on the best targets for combinatorial inter-
vention and the best clinical strategies to
apply to stay ahead of the game. If we do
this, I am conﬁdent that we should make
major improvements in long-term survival














Lymphatic vessels facilitate ﬂuid
homeostasis, immune cell trafﬁck-
ing, and lipid transport, and contrib-
ute to solid tumor progression as
routes of metastasis. Given new
evidence that lymphatic vessels
both correlate with intratumoral
lymphocytes and directly suppress
immune function, I reevaluate the
passive lymphatic vessel paradigm
and discuss its relevance to
antitumor immunity.
The lymphatic vasculature is a unidirec-
tional drainage system that functions to
clear ﬂuid and cells from peripheral tissue.
In tumor microenvironments, lymphatic
vessel growth (lymphangiogenesis) and
remodeling are important steps in cancer
progression that facilitate metastatic dis-
semination to sentinel lymph nodes (LN)
[1]; a poor prognostic for many solid
tumors. However, lymphatic vessels are
also necessary routes of antigen delivery
to LNs for adaptive immunity and yet
demonstrate novel immunomodulatory
functions that may limit these responses.
Immune checkpoint blockade is an effec-
tive treatment for solid tumors, in particular
those with signiﬁcant pre-existing immu-
nity. For patients who achieve objective
responses, this appears to translate into
durable stabilization of their disease; how-
ever, a subset of patients and tumor types
still do not respond [2]. The intratumoral
localization of activated antigen-speciﬁc
CD8+ T cells is enriched in long-term
survivors [3] and clinical responders [2],
indicating that T cell inﬁltration is limiting
